Philippe Huot

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 25

Top Topics

Parkinson Disease

Liquid Chromatography Tandem Mass Spectrometry

Top Venues

Neurodegenerative disease management

Experimental brain research

Naunyn-Schmiedeberg's archives of pharmacology

Journal of neural transmission (Vienna, Austria : 1996)

This page only lists publications with an associated author ORCID identifier.

Publications

Imane Frouni, Esther Kim, Judy Shaqfah, Dominique Bédard, Cynthia Kwan, Sébastien Belliveau, Philippe Huot
[ 3 H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain. Experimental brain research (2024)
Imane Frouni, Esther Kim, Judy Shaqfah, Dominique Bédard, Cynthia Kwan, Sébastien Belliveau, Philippe Huot
[ 3 H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain. Experimental brain research 242 (5) (2024)
Shawn Maddaford, Philippe Huot
Glycine and clozapine: potential relevance for the treatment of Parkinson's disease. Neurodegenerative disease management (2024)
Imane Frouni, Esther Kim, Judy Shaqfah, Dominique Bédard, Cynthia Kwan, Sébastien Belliveau, Philippe Huot
[ 3 H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain. Experimental brain research 242 (5) (2024)
Imane Frouni, Esther Kim, Judy Shaqfah, Dominique Bédard, Cynthia Kwan, Sébastien Belliveau, Philippe Huot
[ 3 H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain. Experimental brain research 242 (5) (2024)
Imane Frouni, Esther Kim, Judy Shaqfah, Dominique Bédard, Cynthia Kwan, Sébastien Belliveau, Philippe Huot
[ 3 H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain. Experimental brain research 242 (5) (2024)
Woojin Kang, Imane Frouni, Cynthia Kwan, Dominique Bédard, Stephen G Nuara, Adjia Hamadjida, Jim C Gourdon, Philippe Huot
Effect of the mGlu 2 positive allosteric modulator biphenyl-indanone A as a monotherapy and as adjunct to a low dose of L-DOPA in the MPTP-lesioned marmoset. The European journal of neuroscience (2024)
Imane Frouni, Esther Kim, Judy Shaqfah, Dominique Bédard, Cynthia Kwan, Sébastien Belliveau, Philippe Huot
[ 3 H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain. Experimental brain research 242 (5) (2024)
Philippe Huot
A discussion with Philippe Huot: the challenges of discovering novel therapies for the treatment of Parkinson's disease. Neurodegenerative disease management (2024)
Imane Frouni, Dominique Bédard, Élodie Bourgeois-Cayer, Adjia Hamadjida, Fleur Gaudette, Francis Beaudry, Philippe Huot
Pharmacokinetic profile of bitopertin, a selective GlyT 1 inhibitor, in the rat. Naunyn-Schmiedeberg's archives of pharmacology (2023)
Jawad Al-Kassmy, Christine Sun, Philippe Huot
5-HT 1A agonists for levodopa-induced dyskinesia in Parkinson's disease. Neurodegenerative disease management (2023)
Cynthia Kwan, Imane Frouni, Dominique Bédard, Adjia Hamadjida, Stephen G Nuara, Jim C Gourdon, Philippe Huot
The 5-HT 2A/2C inverse agonist nelotanserin alleviates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset. The European journal of neuroscience (2023)
Philippe Huot
Targeting metabotropic glutamate receptors for the treatment of Parkinson's disease. Neurodegenerative disease management (2023)
Imane Frouni, Cynthia Kwan, Dominique Bédard, Woojin Kang, Adjia Hamadjida, Stephen G Nuara, Jim C Gourdon, Philippe Huot
Effect of the mGlu 4 positive allosteric modulator ADX-88178 on parkinsonism, psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset. Psychopharmacology (2023)
Lucie Lachance, Philippe Huot
Pemphigoid-like Skin Lesions Following Introduction of Safinamide. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (2022)
Cynthia Kwan, Theodore Kolivakis, Philippe Huot
Dopamine Agonist Withdrawal Syndrome and Suicidality in Parkinson's Disease. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (2022)
Cynthia Kwan, Philippe Huot
An overview of the active clinical trials for Parkinson's disease psychosis. Neurodegenerative disease management 12 (4) (2022)
Stephen G Nuara, Jim C Gourdon, Philippe Huot
Evaluation of the effects of the mGlu 2/3 antagonist LY341495 on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset. Pharmacological reports : PR 74 (4) (2022)
Imane Frouni, Philippe Huot
Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic. Neurodegenerative disease management 12 (4) (2022)
Cynthia Kwan, Stephen G Nuara, Jim C Gourdon, Philippe Huot
Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset. Naunyn-Schmiedeberg's archives of pharmacology 394 (8) (2021)
Philippe Huot, Woojin Kang, Esther Kim, Dominique Bédard, Sébastien Belliveau, Imane Frouni, Cynthia Kwan
Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials. Neurodegenerative disease management 12 (2) (2021)
Stephen G Nuara, Jim C Gourdon, Shawn Maddaford, Philippe Huot
Additive effects of mGluR2 positive allosteric modulation, mGluR2 orthosteric stimulation and 5-HT2AR antagonism on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset. Naunyn-Schmiedeberg's archives of pharmacology 394 (12) (2021)
Imane Frouni, Cynthia Kwan, Stephen G Nuara, Sébastien Belliveau, Woojin Kang, Adjia Hamadjida, Dominique Bédard, Jim C Gourdon, Philippe Huot
Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset. Journal of neural transmission (Vienna, Austria : 1996) 128 (1) (2021)
Francis Beaudry, Philippe Huot
The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results. Journal of neural transmission (Vienna, Austria : 1996) 127 (10) (2020)
Philippe Huot
Monoamine oxidase A inhibition and Parkinson's disease. Neurodegenerative disease management 10 (6) (2020)